“大批中成药将退出市场”是真的吗？

Core Viewpoint - The recent implementation of the "Regulations on the Registration Management of Traditional Chinese Medicine" by the National Medical Products Administration is expected to significantly impact the market for traditional Chinese medicine, with a potential exit of many products by 2031 due to stricter requirements for drug registration and safety information [1][2][5]. Group 1: Policy Implementation and Timeline - The new regulations took effect on July 1, 2023, providing a transition period of three years, with an actual deadline for compliance extending to 2031 due to the five-year drug re-registration cycle [1][5]. - Many companies, including leading firms like Yunnan Baiyao and Tongrentang, are already preparing to meet the new requirements by enhancing their product safety information [1][5]. Group 2: Rationale Behind the Policy - The policy aims to improve drug safety by mandating that traditional Chinese medicine products clearly state contraindications, adverse reactions, and precautions, addressing public concerns about medication safety [2][4]. Group 3: Market Impact and Industry Dynamics - The regulations are not expected to lead to a mass exit of traditional Chinese medicine products; instead, they may encourage companies to focus on their core strengths and improve product quality [4][5]. - The Chinese traditional medicine market is characterized by excessive competition, with over 4,500 production companies and approximately 2,400 traditional Chinese medicine enterprises, leading to a potential consolidation as weaker companies may exit the market [5][6]. - The policy could facilitate a shift from a fragmented market to a more robust and high-quality development phase, aligning better with consumer needs [6].